# Degarelix

Canonical source: https://retacompare.com/encyclopedia/degarelix

Long-acting GnRH antagonist providing immediate testosterone suppression in prostate cancer without flare.

Reference facts

Also known asFirmagon, FE-200486CategoryGnRH & ReproductiveMechanism of actionLong-acting GnRH antagonist providing immediate testosterone suppression in prostate cancer without flare.TargetsGnRH receptor (antagonist)Indications under research or approvedAdvanced prostate cancerRegulatory status (reference entry)FDA-approved (2008)Half-life~53 days (depot at 240 mg)Sequence notesDecapeptide GnRH antagonist Ac-D-2Nal-D-4ClPhe-D-3Pal-Ser-4Aph(L-Hor)-D-4Aph(Cbm)-Leu-ILys-Pro-D-Ala-NH2.Molecular weight (Da)1632Originator / sponsorFerring PharmaceuticalsFirst reported2002
    Primary References

Firmagon FDA label


    Explore research articles about Degarelix


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Firmagon FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022201s015lbl.pdf